DSM focuses its vitamin C production in Dalry, UK
DSM will focus its production of vitamin C at the plant in Dalry. Currently investments are being made to upgrade the plant within the scope of the Vital Project, the integration and transformation program of DSM Nutritional Products. This will lead to important cost reductions and allow for increased raw material flexibility. At the same time DSM is developing flexible alternative sourcing options, including the recently announced intended alliances in China.
Closure of the bulk ascorbic acid plant at the Belvidere site is expected to take place in Q3 2005. The formulation plant in Belvidere will be adjusted to optimize the production of specific product formulations for the North American and other markets. DSM will continue to produce its other products at the Belvidere site, such as formulations for other vitamins and arachidonic acid for baby formula milk.
The above decisions, on top of the measures that are already being taken in Dalry and Belvidere in the framework of the Vital project, will lead to a reduction of the workforce in Belvidere by approximately 150 people.
Topics
Organizations
Other news from the department manufacturing
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.